Key facts
- This page summarizes John M. Evans's Form 3 filing for Verve Therapeutics, Inc. (VERV).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Jun 2021, 19:37.
John M. Evans - 16 Jun 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)
- Reporting relationship
- Director
- Issuer ticker
- VERV
- Reported as of
- 16 Jun 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 16 Jun 2021, 19:37:06 UTC
- Prior SEC filing
- 21 Sep 2021
- Next SEC filing
- 30 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Ashe, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John M. Evans filed Form 3 for Verve Therapeutics, Inc. (VERV) on 16 Jun 2021.
Change
- Previous filing in this sequence was filed on 21 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VERV
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,599
- Exercise price
- $8.98
- Footnotes
- F1
VERV
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,599
- Exercise price
- $2.87
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option was granted on April 1, 2021 for 21,599 shares. The shares underlying the option vest quarterly over 4 years in 16 equal quarterly installments, with the first installment commencing on April 1, 2021.
Footnote F2
The option was granted on September 16, 2020 for 21,599 shares. The shares underlying the option vest quarterly over 3 years in 12 equal quarterly installments, with the first installment commencing on July 1, 2020.
SEC remarks
Exhibit Index: 24.1 Power of Attorney